相关实验视频
Updated: Jun 21, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
降低2型糖尿病心血管风险:非专家需要了解当前指南的内容
1Division of Nephrology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
早期查和心血管疾病 (CVD) 和糖尿病患者相关疾病的管理至关重要. 积极治疗高血压,高血糖和高脂血症可以预防严重的并发症.
科学领域:
- 内分泌学和脏学.
- 心血管医学 心血管医学
- 公共卫生 公共卫生
背景情况:
- 糖尿病和糖尿病前期影响了美国人口的很大一部分,慢性病 (CKD) 和心血管疾病 (CVD) 的共同发病率很高.
- 肥胖是导致高血压,高血糖,高脂血症,代谢综合征和非酒精性脂肪肝疾病等并发症的主要驱动因素,增加了发病率和死亡率.
- 现有的心血管风险管理目标只有很小比例的成年人达到,有种族和民族差异.
研究的目的:
- 审查目前对糖尿病患者心血管疾病 (CVD) 风险管理的建议和护理标准.
- 强调早期诊断和治疗与糖尿病和肥胖相关的并发症的重要性.
- 突出血糖控制,血压,脂质管理和特定药物在预防心脏病进展中的作用.
主要方法:
- 审查美国糖尿病协会 (ADA) 的共识陈述和指导方针.
- 分析糖尿病,肥胖和相关并发症之间的关系.
- 专注于查方案和治疗策略,以减少糖尿病患者心血管疾病风险.
主要成果:
- 美国糖尿病协会 (ADA) 建议对心力衰竭,CKD和糖尿病进行早期查.
- 准则提倡更早地查微专尿症,血压,血糖控制和脂质.
- 综合管理高血糖,高血压和高脂血症是必不可少的.
结论:
- 早期识别和干预是预防糖尿病患者下游目标器官并发症的关键.
- 针对血糖控制,血压,脂质和心保护药物的综合管理策略至关重要.
- 解决糖尿病和肥胖症并发症的聚类对于改善患者的治疗结果和降低死亡率至关重要.
更多相关视频
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
07:51Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes: Symptoms, Diagnosis, and Complications
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Oral Hypoglycemic Agents: Biguanides and Glitazones